日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors

TTI-101(一种首创的口服STAT3抑制剂)治疗晚期实体瘤患者的I期临床试验

Tsimberidou, Apostolia M; Vining, David J; Arora, Sukeshi P; de Achaval, Sofia; Larson, Jeffrey; Kauh, John; Cartwright, Carrie; Avritscher, Rony; Alibhai, Imran; Tweardy, David J; Kaseb, Ahmed O

Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat

维利西呱的临床药代动力学和药效学特征

Fritsch, Achim; Meyer, Michaela; Blaustein, Robert O; Trujillo, Maria E; Kauh, Eunkyung; Roessig, Lothar; Boettcher, Michael; Becker, Corina

Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor

口服生物可利用的大环肽,可抑制 PCSK9 与低密度脂蛋白受体的结合

Douglas G Johns #, Louis-Charles Campeau #, Puja Banka, An Bautmans, Tjerk Bueters, Elisabetta Bianchi, Danila Branca, Paul G Bulger, Inne Crevecoeur, Fa-Xiang Ding, Robert M Garbaccio, Erik D Guetschow, Yan Guo, Sookhee N Ha, Jennifer M Johnston, Hubert Josien, Eunkyung A Kauh, Kenneth A Koeplinger

Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling

贝祖替凡的群体药代动力学分析,为剂量考量和标签说明提供依据

Marathe, Dhananjay D; Jauslin, Petra M; Kleijn, Huub Jan; de Miranda Silva, Carolina; Chain, Anne; Bateman, Thomas; Shaw, Peter M; Abraham, Anson K; Kauh, Eunkyung A; Liu, Yanfang; Perini, Rodolfo F; de Alwis, Dinesh P; Jain, Lokesh

Building an Equitable Future Through Data Disaggregation

通过数据细分构建公平的未来

Kauh, Tina J; Minnis, Terry Ao; Anand, Meeta; Berry, Maya; Gold, Rosalind

Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study.

集落刺激因子-1受体抑制剂在晚期难治性乳腺癌或前列腺癌患者中的免疫调节活性:一项I期研究

Autio Karen A, Klebanoff Christopher A, Schaer David, Kauh John Sae Wook, Slovin Susan F, Adamow Matthew, Blinder Victoria S, Brahmachary Manisha, Carlsen Michelle, Comen Elizabeth, Danila Daniel C, Doman Thompson N, Durack Jeremy C, Fox Josef J, Gluskin Jill S, Hoffman David M, Kang Suhyun, Kang Praneet, Landa Jonathan, McAndrew Philomena F, Modi Shanu, Morris Michael J, Novosiadly Ruslan, Rathkopf Dana E, Sanford Rachel, Chapman Sonya C, Tate Courtney M, Yu Danni, Wong Phillip, McArthur Heather L

A Multi-Component Analysis of CPTED in the Cyberspace Domain

网络空间领域犯罪预防环境设计的多组件分析

Lee, Jemin Justin; Go, Myong-Hyun; Kim, Yu-Kyung; Joo, Minhee; Seo, JeongEun; Oh, Haengrok; Kauh, Janghyuk; Lee, Kyungho

Teacher Physical Education Practices and Student Outcomes in a Sample of Middle Schools Participating in the Presidential Youth Fitness Program

参与总统青年健身计划的部分中学教师体育教学实践与学生成绩

Lucas, Isabela Ribeiro; Harris, Carole; Lee, Sarah; Wargo, Jane; Barnes, Seraphine Pitt; Kauh, Tina J; Iachan, Ronaldo

Pharmacokinetic-pharmacodynamic (dipeptidyl peptidase-4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once-weekly administered omarigliptin

建立药代动力学-药效学(二肽基肽酶-4抑制)模型,以支持糖尿病患者(包括肾功能不全患者)每周一次给药的奥马格列汀的剂量合理性。

Jain, Lokesh; Chain, Anne S Y; Tatosian, Daniel A; Hing, Jeremy; Passarell, Julie A; Kauh, Eunkyung A; Lai, Eseng

Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203)

一项基于肿瘤胸苷酸合成酶表达的治疗选择在既往未接受治疗的转移性结直肠癌患者中进行的 II 期研究:ECOG-ACRIN 癌症研究组的一项试验 (E4203)

Meropol, Neal J; Feng, Yang; Grem, Jean L; Mulcahy, Mary F; Catalano, Paul J; Kauh, John S; Hall, Michael J; Saltzman, Joel N; George, Thomas J Jr; Zangmeister, Jeffrey; Chiorean, Elena G; Cheema, Puneet S; O'Dwyer, Peter J; Benson, Al B 3rd